Q-omics provides the consensus-scored CD320 profile across patient tissues and cancer cell-line models. CD320 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CD320 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CD320 RNA expression shows 18,376 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, COAD, and THYM as cancer lineages where CD320 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD320 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD320 survival associations across molecular data types. CD320 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD320 RNA expression–survival associations across cancer types. High CD320 expression shows unfavorable associations in UCS, LIHC, KICH, MESO, ACC and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for CD320 RNA expression.
This table summarizes CD320 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CD320. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD320 shows higher tumor expression in COAD, HNSC, KIRP, THCA, LIHC and KIRC. The COAD box plot shows higher CD320 RNA expression in tumor versus normal tissue (log2 FC = +1.421, t-test p < 0.001).
This table shows molecular features associated with CD320 in patient tissues and cancer cell lines. In patient samples, CD320 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD320 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
